In Vitro Toxicity Testing Market: Global Size, Share, Trends, Growth and Forecast 2022-2032
In 2021, the global in vitro toxicity testing market size was estimated at around USD 15.5 billion. Further, the market is anticipated to grow at a rate of 9.5% during forecast period. The use of animal testing models is now limited due to the evolution of the 3D cell culture system that mimics host physiology and enables safe testing of new compounds in the in vitro environment. Thus, the market for In Vitro toxicity testing will grow shortly at a good pace.
There are growing ethical concerns regarding animal testing, and due to the efforts of several animal welfare organizations, there have been replacement or reduction of animal testing within vitro toxicity testing. There is high cost in animal testing, and also it is highly time-consuming, and there are many safety risks for the animals are involved. In many industries, there has been an increasing focus on developing and using non- animal-based testing methods. In vitro toxicity testing enables rapid assessment of safety and offer cost-saving as well as time-saving advantages. In vitro toxicity testing is preferred by many drug developers. There is a positive adoption rate in vitro toxicity testing due to integrating systems biology, toxicogenomics, computational toxicology, and epigenetics. There are lucrative avenues for market growth as significant players expand their in vitro toxicity testing offerings.
In 2021, the cell culture technology dominated the market as it serves as an excellent model for examining toxic effects since it provides consistent samples and reproducible results. This enables early-stage detection of toxicity in the drug development process. Leading the extensive applications, cell cultures are increasingly replacing animal testing. It is expected that rapid advancement in biomedical sciences will result in the development of newer and advanced in vitro test strategies and for hazard characterization. Testing of toxicity is becoming advanced with various cutting-edge technologies helping the process, and it is currently poised to take advantage of good revolutions in biotechnology. With advances in biotechnology, toxicity testing applications are set to increase, resulting in a demand for the same in the market. To understand biological responses to chemicals in human tissues, several field and techniques are emerging. This is expected to drive the In-vitro Toxicity testing market's growth shortly and the present.
For any healthcare molecule's approval, the screening process is quite difficult many molecules fail in the toxicity study stage and are barred from entering the market. The method of scientifically analyzing the effects of lethal or toxic chemical material either on mammalian cells on cultured bacteria is known as In vitro toxicity testing. These methods are mainly performed to identify potentially harmful chemicals and confirm the deficiency of certain toxic properties. This is in the initial stages of developing possibly useful novel substances, which include therapeutic drugs, agricultural chemicals, and even food additives. There is expansion and development of in vitro assay systems due to recent inventions and advances in human cell culture exposure. These are predictive, demonstrative, and suitable for toxicity screening of many chemicals, including nano materials and airborne materials. To examine the toxic properties of various compounds and mixtures, In vitro toxicology involves the usage of cells and tissues grown or maintained in the controlled laboratory environment, and it enables to examine the toxicity of xenobiotics at the necessary level of the cell. This is without involving the interplay of complex physiological systemic effects found in the entire organism.
Key Market Players
The following are the key market players:
- Thermo Fisher Scientific Inc. (US),
- Covance (US),
- Bio-Rad Laboratories, Inc. (US),
- GE Healthcare (US),
- Eurofins Scientific SE (Luxembourg),
- Merck KGaA (Germany),
- Charles River Laboratories International, Inc. (US),
- Catalent, Inc. (US),
- Cyprotex (UK),
- SGS S.A. (Switzerland),
- QIAGEN N.V. (Germany),
- Promega Corporation (US),
- Gentronix Limited (UK),
- BioIVT (US), and
- MB Research Laboratories (US).
By Product & Service
- Bacterial Toxicity Assays
- Enzyme Toxicity Assays
- Cell-based Elisa & Western Blots
- Receptor-binding Assays
- Tissue Culture Assays
- Other Assays
- Cellular Assays
- Biochemical Assays
- In Silico Models
- Ex Vivo Models
By Toxicity Endpoint & Test
- Skin Irritation, Corrosion, & Sensitization
- Genotoxicity Testing
- Cytotoxicity Testing
- Ocular Toxicity
- Organ Toxicity
- Phototoxicity Testing
- Dermal Toxicity
- Other Toxicity Endpoints & Tests
- Pharmaceuticals & Biopharmaceuticals
- Cosmetic & Household Products
- Cell Culture Technologies
- High-throughput Technologies
- North America (The U.S. and Canada)
- Europe (U.K., Germany, France, Italy, Spain, Russia, Poland, Turkey, Switzerland, and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, South Korea, Vietnam, Philippines, Malaysia, Indonesia, Thailand, and Rest of Asia Pacific)
- Latin America (Brazil, Mexico, Columbia, Argentina, Chile, and Rest of Latin America)
- Middle East & Africa (South Africa, Saudi Arabia, UAE, Oman, Egypt, and Rest of Middle East & Africa)
- Covance in the year 2019 launched a lab solution with its FSPx offering.
- Merck in the year 2019 acquired BSSN software which is German Informatics lab.
Powered by Froala Editor